Why did third-quarter revenue meet expectations but still decline year over year?

  • Zai Lab’s third-quarter product revenue was $108 million, down 7% year over year and up 2% sequentially. Goldman Sachs expected $105 million, while the Visible Alpha consensus was $107 million. Revenue therefore met both benchmarks, but remained lower year over year.
  • Growth came from some products: NUZYRA revenue was $21 million, up 37% year over year and 23% sequentially; XACDURO revenue was $8 million, up 31% year over year and 5% sequentially, though it remained subject to supply constraints; KarXT, launched in June, generated revenue of $2 million, above $600 thousand in the second quarter.
  • Mature products had mixed results: Zejula revenue was $32 million, down 24% year over year, and VYVGART revenue was $24 million, down 13%; both rose 1% sequentially. OPTUNE revenue was $8 million, down 38% year over year and 36% sequentially. The report linked its decline to intensifying domestic competition.

What changes are needed for revenue to return to growth in 2027?

  • Management reiterated its view that revenue would return to meaningful growth in 2027, citing several factors: subcutaneous VYVGART and KarXT are expected to gain momentum with support from the National Reimbursement Drug List; Zejula is seeking to regain patient share; and XACDURO is expected to accelerate growth as supply constraints ease. In other words, a return to growth requires newer products to ramp up alongside improvements in existing products.
  • Third-quarter EBIT loss was $63 million, below Goldman Sachs’ forecast of $67 million; however, gross margin fell from 55% in the second quarter to 52%, including an inventory write-down of $7.5 million, primarily related to VYVGART. Operating expenses were $120 million, up 2% year over year; higher clinical spending was partly offset by lower personnel costs.

What are the key clinical milestones for zoci?

  • The 1b-phase data presented at ESMO 2026 support the company’s selection of a chemotherapy-free doublet regimen of zoci at 1.6 mg/kg plus atezo for global Phase III development. Goldman Sachs views zoci as a core source of value in Zai Lab’s pipeline; the company expects three global pivotal programs to be initiated or underway by the end of 2026.
  • The DLLEVATE Phase III study in second-line and later small-cell lung cancer is underway. Management expects a formal interim analysis after approximately 200 patients have been followed for at least 6 months to support a submission for accelerated approval or a biologics license application in 2027. The Phase III study of zoci plus PD-L1 for first-line small-cell lung cancer is expected to start before the end of 2026.
  • For the study in second-line and later extrapulmonary neuroendocrine carcinoma, the report lists an objective response rate of 38.2%, compared with a historical range of 10%–20%. Enrollment has been completed in a potential registrational expansion cohort of approximately 100 patients. Management expects to report data in the first half of 2027, supporting a US accelerated-approval application.

What underpins Goldman Sachs’ bullish view and price target?

  • Goldman Sachs maintains its Buy rating and raises its 12-month price target for Zai Lab ADS from $34.50 to $34.50?
  • Goldman Sachs describes the company as shifting from a licensing-in model focused mainly on China to a dual-engine model combining internal R&D and licensing, oriented toward global opportunities. Its estimates suggest that more than 10 late-stage assets in the China business could generate $1 billion in sales by 2030; if zoci is out-licensed in a typical licensing deal, its global potential could add more than $2 billion in value for the company.
  • Goldman Sachs maintains its Buy rating, raising its ADS price target from $32.70 to $34.50 and its H-share price target from HK$25.49 to HK$26.89. The valuation uses a discounted cash flow model, with an assumed weighted average cost of capital of 11% and a perpetual growth rate of 2%. The report lists key constraints including clinical or regulatory setbacks or delays, as well as changes in drug pricing, commercialization execution, and import supply chains.

Related topics